Please login to view this media
- Talk
- 22/09/2021
- UK
Does the Modified Glasgow Prognostic Score aid in the Management of Patients undergoing Surgery for a Soft Tissue Sarcoma? An International Multi-Centre Study
Description
In this presentation, Omer Alanie discusses an international multicenter study focusing on the predictive value of the modified Glasgow Prognostic Score (mGPS) for patients undergoing surgery for soft tissue sarcoma. The study acknowledges that despite advancements in treatment, up to 50% of patients with soft tissue sarcoma can succumb to the disease, indicating a dire need for effective prognostic tools. The mGPS, developed for carcinomas approximately 20 years ago, combines C-reactive protein (CRP) and albumin levels to assess inflammation and its potential impact on cancer outcomes.
The analysis encompasses data from 493 patients across multiple centers over a seven-year period, filtering out those with metastatic disease or inadequate follow-up to ensure a robust dataset. Findings reveal that both univariate and multivariate analyses display the mGPS as a reliable indicator of survival, along with other factors such as tumor size and grade. In particular, patients with a normal mGPS exhibited a significantly better prognosis compared to those with an abnormal score.
The implications of using mGPS are extensive, suggesting potential modifications in treatment approaches, including targeting at-risk patients for nutritional support and considering less aggressive surgical options for those with limited life expectancy. The study recommends integrating the mGPS into the initial staging process for soft tissue sarcoma due to its simplicity, reliability, and ability to provide valuable insights prior to surgery.